We last wrote about GeNeuro in January, when they announced the launch of an IPO for their Multiple Sclerosis phase IIb trial. Now, as of yesterday they are listed on the Euronext Paris market.
GeNeuro (in Geneva) is developing therapies and diagnostic tools for diseases associated with the expression of the human endogenous retrovirus MSRV, such as the Multiple Sclerosis (MS).
Previously, this biotech and the French Servier have signed a partnership to develop first medicine addressing a causal factor of MS.
Shares are opening at €13 each, raising a total of €33M and its Market cap already sits at €190M – definitely a very nice move.
GeNeuro is the first Swiss company to be listed on the Euronext Paris in a very long time…and in fact, it’s been nearly 6 months since we last had a Biotech IPO in Europe at all.
This is in part due to the financial insecurity at the moment,